12 Month Price Forecast For INCR
Distance to INCR Price Forecasts
INCR Price Momentum
๐ค Considering InterCure (INCR)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 11, 2025 3:40 AM UTC
INCR Analyst Ratings & Price Targets
INCR has shown a year-to-date change of 6.9% and a 1-year change of 9.0%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for INCR. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
INCR Analyst Consensus
INCR Price Target Range
Latest INCR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for INCR.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Apr 12, 2023 | TD Cowen | Vivien Azer | Outperform | Maintains | $5.00 |
Dec 11, 2017 | Barclays | Jack Meehan | Equal-Weight | Initiates | $40.00 |
Nov 14, 2017 | Credit Suisse | Erin Wilson | Outperform | Maintains | $54.00 |
Nov 13, 2017 | Keybanc | Donald Hooker | Overweight | Maintains | $46.00 |
Nov 10, 2017 | Baird | Eric Coldwell | Outperform | Maintains | $46.00 |
Aug 17, 2016 | Jefferies | Buy | Maintains | $55.00 | |
Aug 12, 2016 | Goldman Sachs | Buy | Maintains | $62.00 | |
Apr 18, 2016 | Avondale Partners | Market Perform | Maintains | $47.00 | |
Sep 1, 2015 | Jefferies | Buy | Upgrade | $51.00 | |
May 27, 2015 | Jefferies | Hold | Maintains | $37.00 | |
Feb 12, 2015 | Baird | Outperform | Upgrade | $29.00 |
Stocks Similar to InterCure Ltd.
The following stocks are similar to InterCure based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
InterCure Ltd. (INCR) Financial Data
InterCure Ltd. has a market capitalization of $79.40M with a P/E ratio of 22.2x. The company generates $76.50M in trailing twelve-month revenue with a -24.1% profit margin.
Revenue growth is -38.6% quarter-over-quarter, while maintaining an operating margin of +8.2% and return on equity of -13.6%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

InterCure Ltd. (INCR) Company Overview
About InterCure Ltd.
Produces and distributes pharmaceutical-grade cannabis.
The company generates revenue through the research, cultivation, production, and distribution of cannabis products for medical use. It offers a range of products including dried cannabis inflorescences and cannabis extracts mixed with oil, catering to both local and international markets.
InterCure Ltd. was incorporated in 1994 and is headquartered in Herzliya, Israel. In addition to its core operations in cannabis, the company also invests in the biomed sector, indicating a diversified approach to growth and innovation.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
270
CEO
Mr. Alexander Rabinovich
Country
Israel
IPO Year
2021
Website
www.intercure.coInterCure Ltd. (INCR) Latest News & Analysis
Funding for facility expansion may reach NIS 107M post-war, with investments from CEO Alexander Rabinovich and lead investors Yaron Yakobi and Tzahi Hagag becoming significant shareholders.
Increased funding for facility expansion signals growth potential, bolstered by key shareholder investments, which may enhance company stability and attract further investor interest.
Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company
4 months agoInterCure Ltd. (INCR) demonstrated resilience in its H1 2024 performance despite significant challenges, as noted by equity research from Zuanic & Associates.
InterCure Ltd.'s strong H1 2024 performance amid challenges signals potential stability and growth, attracting investor interest and confidence in its future prospects.
InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million
5 months agoInterCure Ltd. (NASDAQ: INCR) announced its financial and operating results for H1 2024, ending June 30. Details are reported in New Israeli Shekels (NIS).
InterCure's financial results can impact stock performance, indicating growth potential or operational challenges. Investors may adjust positions based on these insights.
InterCure Ltd. (NASDAQ: INCR) has signed a strategic agreement with Cookies to cultivate, manufacture, and distribute Cookies' branded cannabis products in 8 licensed pharmacies.
InterCure's partnership with Cookies enhances its product offerings and market reach, potentially increasing revenue and solidifying its position in the growing cannabis industry.
InterCure, a leading Israeli pharmaceutical and medical cannabis company, maintained operations and reported a positive 2023 ER despite war impacts, and will receive full compensation from the government.
InterCure's resilience amid conflict and a positive earnings report, coupled with government compensation, suggests stability and potential growth, making it an attractive prospect for investors.
InterCure Ltd. (NASDAQ: INCR) will participate in the Canaccord Genuity 8th Annual Global Cannabis Conference on May 23, 2024, in New York City, showcasing the company alongside industry leaders.
InterCure's participation in a prominent cannabis conference highlights its industry presence and potential for growth, attracting investor attention to its strategic initiatives.
Frequently Asked Questions About INCR Stock
What is InterCure Ltd.'s (INCR) stock forecast for 2025?
Analyst forecasts for InterCure Ltd. (INCR) are not currently available. The stock is trading at $1.70.
Is INCR stock a good investment in 2025?
According to current analyst ratings, INCR has 8 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.70. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for INCR stock?
Price predictions from Wall Street analysts for INCR are not currently available. The stock is trading at $1.70.
What is InterCure Ltd.'s business model?
The company generates revenue through the research, cultivation, production, and distribution of cannabis products for medical use. It offers a range of products including dried cannabis inflorescences and cannabis extracts mixed with oil, catering to both local and international markets.
What is the highest forecasted price for INCR InterCure Ltd.?
Price targets from Wall Street analysts for INCR are not currently available. The stock is trading at $1.70.
What is the lowest forecasted price for INCR InterCure Ltd.?
Price targets from Wall Street analysts for INCR are not currently available. The stock is trading at $1.70.
What is the overall INCR consensus from analysts for InterCure Ltd.?
The overall analyst consensus for INCR is bullish. Out of 6 Wall Street analysts, 8 rate it as Buy, 4 as Hold, and 0 as Sell.
How accurate are INCR stock price projections?
Stock price projections, including those for InterCure Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.